محققان دانشگاه بریستول اولیندور آزمايش واکسن جدیدی برا ی درمان ام اس را با موفقیت پشت سر گذاشتند. این واکسن که باتنظیم سیستم ایمنی از واکنش بدن نسبت به میلین و تخریب آن میکاهد بخوبی در این گروه آزمایشی از بیماران تجویز شد وهیچ واکنش جانبی بهمراه نداشت و نتایج آزمایش خون بیماران رضایت بخش بود . ترجمه كل مقاله در دست تهيه ميباشد كه به محض آماده شدن در همينجا وارد خواهد شد
British researchers have hailed the first clinical trial of a radical new approach to the treatment of multiple sclerosis, which affects some 85,000 people in the UK and as many as 2.5m worldwide.
Scientists from Bristol University and its spin-out company Apitope on Wednesday disclose their analysis of the initial safety tests on six patients of the experimental MS vaccine, code-named ATX-MS-1467, which rebalances the immune system.
EDITOR’S CHOICE
Analysis: The ethics of offshoring clinical trials - Jan-28
Measures to limit drug marketing questioned - Jan-18
Call for rethink over drug assessments - Jan-10
Push for 10% drug price cut - Jan-07
MS is the most common disabling disease in young adults. It is a disorder of the immune system, which damages the myelin sheath protecting nerve fibres and produces a wide range of neurological problems. But the ultimate cause is unknown and the progress of the disease is unpredictable.
All the patients tolerated the vaccine well and showed no adverse side-effects. Blood tests confirmed the treatment had reduced the underlying auto-immune reaction causing MS symptoms. And, although the trial was not designed to test the vaccine’s effectiveness, two patients did show clinical benefits; one who was going blind had a marked improvement in vision.
Five MS drugs are licensed in the UK. According to the Multiple Sclerosis Society these treatments can reduce the rate at which patients relapse but they do not benefit people with progressive disease or those who are already severely disabled.
Laura Bell of the MS Society said: “Finding new treatment for people with progressive forms of MS is an important goal for MS research and we are encouraged that studies are now tackling this. The Apitope study is in the early stages and we look forward to the results of the phase two clinical trials.”
Keith Martin, Apitope chief executive, said the phase two trial of ATX-MS-1467 would start this year with about 80 patients in south-west England and last about two years. A diagnostic blood test for MS is also being developed.
Apitope’s approach is based on 20 years of research by David Wraith, professor of experimental pathology at Bristol University. The vaccine works by retuning the immune system so it no longer overreacts to patients’ own myelin protein.
Prof Wraith said this approach was more specific – and likely to carry fewer side-effects – than existing MS drugs that suppressed the immune system or reduced nerve inflammation.
Copyright The Financial Times Limited 2008
Scientists from Bristol University and its spin-out company Apitope on Wednesday disclose their analysis of the initial safety tests on six patients of the experimental MS vaccine, code-named ATX-MS-1467, which rebalances the immune system.
EDITOR’S CHOICE
Analysis: The ethics of offshoring clinical trials - Jan-28
Measures to limit drug marketing questioned - Jan-18
Call for rethink over drug assessments - Jan-10
Push for 10% drug price cut - Jan-07
MS is the most common disabling disease in young adults. It is a disorder of the immune system, which damages the myelin sheath protecting nerve fibres and produces a wide range of neurological problems. But the ultimate cause is unknown and the progress of the disease is unpredictable.
All the patients tolerated the vaccine well and showed no adverse side-effects. Blood tests confirmed the treatment had reduced the underlying auto-immune reaction causing MS symptoms. And, although the trial was not designed to test the vaccine’s effectiveness, two patients did show clinical benefits; one who was going blind had a marked improvement in vision.
Five MS drugs are licensed in the UK. According to the Multiple Sclerosis Society these treatments can reduce the rate at which patients relapse but they do not benefit people with progressive disease or those who are already severely disabled.
Laura Bell of the MS Society said: “Finding new treatment for people with progressive forms of MS is an important goal for MS research and we are encouraged that studies are now tackling this. The Apitope study is in the early stages and we look forward to the results of the phase two clinical trials.”
Keith Martin, Apitope chief executive, said the phase two trial of ATX-MS-1467 would start this year with about 80 patients in south-west England and last about two years. A diagnostic blood test for MS is also being developed.
Apitope’s approach is based on 20 years of research by David Wraith, professor of experimental pathology at Bristol University. The vaccine works by retuning the immune system so it no longer overreacts to patients’ own myelin protein.
Prof Wraith said this approach was more specific – and likely to carry fewer side-effects – than existing MS drugs that suppressed the immune system or reduced nerve inflammation.
Copyright The Financial Times Limited 2008
هیچ نظری موجود نیست:
ارسال یک نظر